- Home
- TARA vs SGMO Comparison
TARA vs SGMO Comparison
Compare TARA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | SGMO |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.5M | 155.1M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | TARA | SGMO |
|---|---|---|
| Price | $5.50 | $0.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $20.33 | $4.71 |
| AVG Volume (30 Days) | 1.3M | ★ 9.2M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $32,875,000.00 |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.77 | $0.38 |
| 52 Week High | $7.82 | $2.84 |
Technical Indicators
Market Signals| Indicator | TARA | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 43.14 |
| Support Level | $5.07 | $0.49 |
| Resistance Level | $6.37 | $0.51 |
| Average True Range (ATR) | 0.46 | 0.04 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 15.26 | 29.28 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.